Is It Safe for Myeloma Patients to Stop Maintenance Therapy?

Published on

Topics include: Treatments

Can multiple myeloma patients stop maintenance therapy if their blood markers are low? Is there a patient subset that requires less maintenance treatment? Noted myeloma expert Dr. Ajay Nooka, from the Winship Cancer Institute, discusses clinical trial data on maintenance therapy after a transplant, patients who achieve minimal residual disease (MRD) negativity, and the potential for relapse. Watch now to find out more.

This town meeting is sponsored by Amgen, Janssen Pharmaceuticals and Adaptive Biotechnologies. It is produced by Patient Power in partnership with Winship Cancer Institute of Emory University.

View more programs featuring and

Produced in association with Winship Cancer Institute

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

What they did was this is a French study where they gave maintenance for a limited duration of time. They gave the maintenance for a year, and they checked for MRD negativity in all these patients.  So everybody that achieved the greatest MRD depth of response at 10 to the part of minus 6, which is one in a million cells they're not able to find, even those patients, 20 of them, 20 percent of them dropped down for the disease to relapse after they stopped the maintenance. 

So that is one thing that, as Dr. Kaufman pointed previously, the majority of the patients who achieved MRD negativity of 10 to the power of minus 6 are the ones that went through the transplant, but stopping the maintenance should not be the goal, should not be the indication of when you reach 10 to the power of minus 6. 

So I think we're very early in the stage at this point of trying to say define those starting groups. Who are those patients who can—who we can safely stop all this maintenance as we all agree that there is a subset of patients that don't need to be on maintenance for longer, but this is too early to make the decision, and in the year, yes, there will be an answer to this question.   

Dr. Nooka:

Yep.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Where Is Research Today on BiTEs and CAR-T Cell Therapy?

How are researchers harnessing the power of a patient’s T cells to treat myeloma? Watch now to hear myeloma experts Dr. Gareth Morgan and Dr. Mohit Trikha discuss recent innovations made in immunotherapy through the use of molecular biology and genetic engineering.

Published:

Developments in Myeloma: What Are BiTEs?

How can BiTES benefit myeloma patients? Noted myeloma expert Dr. Jonathan Kaufman explains how the immunotherapy works to treat multiple myeloma and where research is today. Watch now to find out more.

Published:

How Do Young Adults With Multiple Myeloma Tolerate Treatment?

Do younger myeloma patients respond to treatment differently? Tune in to hear myeloma experts Dr. Jonathan Kaufman and Dr. Rafael Fonseca share their knowledge.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on February 18, 2019